Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neil Rabin

Showing results (41-50 of 77) with videos related to

Pageof 8
Sort By:
British Journal of Haematology|June 15, 2020
Association of hypertension and cardiac events in patients with multiple myeloma receiving carfilzomib: practical management recommendationsSelina J Chavda, Rachael Pocock, Simon Cheesman, et al.
Leukemia & Lymphoma|August 4, 2021
Salvage second autologous stem cell transplant for relapsed multiple myeloma in the novel agent era benefits a subset of patients: single-center UK experienceHuw Richards, Selina J Chavda, William Wilson, et al.
British Journal of Haematology|November 25, 2020
DT-PACE/ESHAP chemotherapy regimens as salvage therapy for multiple myeloma prior to autologous stem cell transplantationLouise Ainley, Selina J Chavda, Nicholas Counsell, et al.
Ejhaem|October 17, 2024
Outcomes of melphalan 140 mg/m<sup>2</sup> followed by autologous stem cell transplantation in multiple myeloma patients with co-morbidities: Single-centre experienceDario Melotti, Samir Asher, Ethan Troy-Barnes, et al.
British Journal of Haematology|February 18, 2017
Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experienceNicola Maciocia, Andrew Melville, Simon Cheesman, et al.
European Radiology|June 29, 2017
Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib inductionArash Latifoltojar, Margaret Hall-Craggs, Alan Bainbridge, et al.
British Journal of Haematology|May 5, 2022
A UK consensus algorithm for early treatment modification in newly diagnosed systemic light-chain amyloidosisSriram Ravichandran, Shameem Mahmood, Brenden Wisniowski, et al.
British Journal of Haematology|July 30, 2015
Time to redefine MyelomaGuy Pratt, Stella Bowcock, Andrew Chantry, et al.
British Journal of Haematology|July 10, 2018
A new prognostic model for myeloma patients relapsing from upfront autologous transplantation based on ISS and PFS1Selina J Chavda, Paul M Maciocia, Pavlina Mesiri, et al.
British Journal of Haematology|May 22, 2020
Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapyGordon Cook, A John Ashcroft, Guy Pratt, et al.
Pageof 8

Showing results (41-50 of 77) with videos related to

Sort By:
Pageof 8
British Journal of Haematology|June 15, 2020
Association of hypertension and cardiac events in patients with multiple myeloma receiving carfilzomib: practical management recommendationsSelina J Chavda, Rachael Pocock, Simon Cheesman, et al.
Leukemia & Lymphoma|August 4, 2021
Salvage second autologous stem cell transplant for relapsed multiple myeloma in the novel agent era benefits a subset of patients: single-center UK experienceHuw Richards, Selina J Chavda, William Wilson, et al.
British Journal of Haematology|November 25, 2020
DT-PACE/ESHAP chemotherapy regimens as salvage therapy for multiple myeloma prior to autologous stem cell transplantationLouise Ainley, Selina J Chavda, Nicholas Counsell, et al.
Ejhaem|October 17, 2024
Outcomes of melphalan 140 mg/m<sup>2</sup> followed by autologous stem cell transplantation in multiple myeloma patients with co-morbidities: Single-centre experienceDario Melotti, Samir Asher, Ethan Troy-Barnes, et al.
British Journal of Haematology|February 18, 2017
Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experienceNicola Maciocia, Andrew Melville, Simon Cheesman, et al.
European Radiology|June 29, 2017
Whole-body MRI quantitative biomarkers are associated significantly with treatment response in patients with newly diagnosed symptomatic multiple myeloma following bortezomib inductionArash Latifoltojar, Margaret Hall-Craggs, Alan Bainbridge, et al.
British Journal of Haematology|May 5, 2022
A UK consensus algorithm for early treatment modification in newly diagnosed systemic light-chain amyloidosisSriram Ravichandran, Shameem Mahmood, Brenden Wisniowski, et al.
British Journal of Haematology|July 30, 2015
Time to redefine MyelomaGuy Pratt, Stella Bowcock, Andrew Chantry, et al.
British Journal of Haematology|July 10, 2018
A new prognostic model for myeloma patients relapsing from upfront autologous transplantation based on ISS and PFS1Selina J Chavda, Paul M Maciocia, Pavlina Mesiri, et al.
British Journal of Haematology|May 22, 2020
Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapyGordon Cook, A John Ashcroft, Guy Pratt, et al.
Pageof 8